In the liquid biopsy assessment of the p. T790M mutation performed as part of the TIGER-X and TIGER-2 trials, which evaluated the safety and efficacy of rociletinib, a third-generation EGFR TKI, in patients with EGFR mutant lung cancers progressing after first-line TKI, the GUARDANT360® 70-gene NGS panel was used to analyze cfDNA. This evidence concerns the gene EGFR and lung carcinoma.